SCHEMBL6812966

SCHEMBL6812966

COc1ccc(/C=C2\Oc3c(ccc(O)c3O)C2=O)cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.70
PARP1 P09874 1/20 0.63
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
NPC1 O15118 1/20 0.61
USP2 O75604 1/20 0.61
POLB P06746 1/20 0.61
GAA P10253 1/20 0.61
MAPT P10636 1/20 0.61
RECQL P46063 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 1/20 0.61
STK17B O94768 2/20 0.60
TUBB4A P04350 1/20 0.60
TUBB P07437 1/20 0.60
TUBA3C P0DPH7 1/20 0.60
TUBA1B P68363 1/20 0.60
TUBA4A P68366 1/20 0.60
TUBB4B P68371 1/20 0.60
TUBB3 Q13509 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6610601 1.00 APP (0.70) APPPARP1KDM4EMEN1NPC1
SCHEMBL6808169 0.94 APP (0.72) APPPARP1KDM4EMEN1NPC1
SCHEMBL6808167 0.94 APP (0.72) APPPARP1KDM4EMEN1NPC1
SCHEMBL6812733 0.93 APP (0.74) APPKDM4EMEN1NPC1USP2
SCHEMBL6812730 0.93 APP (0.74) APPKDM4EMEN1NPC1USP2
SCHEMBL6612304 0.91 STK17B (0.71) APPPARP1STK17B
SCHEMBL6612302 0.91 STK17B (0.71) APPPARP1STK17B
SCHEMBL6809276 0.91 APP (0.67) APPKDM4EMEN1NPC1USP2
SCHEMBL6613036 0.91 APP (0.67) APPKDM4EMEN1NPC1USP2
SCHEMBL6812934 0.90 APP (0.66) APPKDM4EMEN1NPC1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US claimed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132807-A1 Aurones as telomerase inhibitors TERT, TERF2, TERF2IP APP 3533/4885PARP1 11/4885KDM4E 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.